期刊文献+

区域性动脉灌注化疗对胰腺癌bcl-2、bax基因的影响 被引量:17

Effects of regional intra-arterial chemotherapy on bcl-2 and bax expression in pancreatic cancers
原文传递
导出
摘要 目的 探讨区域性动脉灌注化疗对胰腺癌bcl 2、bax基因表达的影响 ,寻找胰腺癌治疗的新手段。方法 应用TUNEL法检测 3 2例未经区域性动脉灌注化疗和 19例经区域性动脉灌注化疗的胰腺癌细胞凋亡指数 (AI) ;并采用免疫组织化学方法检测区域性动脉灌注化疗对胰腺癌细胞bcl、bax基因表达的影响。结果 区域性动脉灌注化疗组胰腺癌细胞AI比未区域性动脉灌注化疗组明显升高 ( 0 65 %vs 1 10 % ,P <0 0 5 ) ;与未区域性动脉灌注化疗组相比 ,区域性动脉灌注化疗组肿瘤细胞bcl 2基因表达明显减少 ( 3 6 7%vs 75 0 % ,P <0 0 5 ) ,而bax基因的表达显著增加 ( 73 6%vs3 4 0 % ,P <0 0 5 )。结论 区域性动脉灌注化疗可以诱导胰腺癌肿瘤细胞凋亡的增加 ,是胰腺癌综合治疗的有效措施之一。 Objective To investigate the effects of intra-arterial chemotherapy on Bcl 2 and Bax expression in pancreatic cancers to seek new approaches for treatment of pancreatic cancer. Methods Apoptotic index (AI) was detected by terminal-deoxynucleotide transferase mediated d-UTP nick end labeling (TUNEL) and expression of Bcl-2 and Bax with immunohistochemistry in 10 cases of pancreatic cancer treated by intra-arterial chemotherapy (group A) and 32 cases without the treatment (group B). Results AI was significantly higher in group A than in group B (P<0.05). The expression of Bcl-2 was markedly decreased but that of Bax remarkably increased in group A as compared with group B (P<0.05). Conclusions Intra-arterial chemotherapy can upregulate apoptosis of pancreatic cancer cells.
出处 《中华肝胆外科杂志》 CAS CSCD 2001年第3期147-149,共3页 Chinese Journal of Hepatobiliary Surgery
关键词 胰腺肿瘤 介入治疗 细胞凋亡 BCL-2基因 BAX基因 区域性动脉灌注化疗 Pancreatic neoplasms Intra-arterial chemotherapy Apoptosis
  • 相关文献

参考文献1

二级参考文献18

  • 1郑扶民,陈英忠.未能切除的胰腺癌行区域性导向化疗临床应用报告[J].中国实用外科杂志,1995,15(4):213-215. 被引量:14
  • 2Ahlgren JD, Chemotherapy of pancratic carcinoma.Cancer,1996,78(3):654.
  • 3O'connell MJ. Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol. 1985, 3(3) : 1032.
  • 4Ishikawa O, Ohigashi H, Sasaki Y,et al.Liver perfusion chemotherapy vis both hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.Am J Surg, 1994,168(4):361.
  • 5Gastrointestinal tumor study group, phase Ⅱ studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil J Clin Oncol, 1986,4(5):1794 .
  • 6Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil doxorubicin and mitomycin,JAMA, 1985,253(10):2061.
  • 7Plunkett W, Huang P, Xu YZ et al . Gemcitabine: metabolism,mechanisms of action and selfpotentiation. Semi Oncol, 1995,22(4 Suppl 11):3.
  • 8Moore M, A randomized trial of gemcitabine (GEM)versus 5-Fu as first line therapy in advanced pancreatic cancer, Proc Am Soc Clin Oncol, 1995,14(1):199.
  • 9Rothenberg ML. A phase Ⅱ trial of gemcitabine in patients wich 5-Fu-refractory pancreas cancer Ann Oncol,1996,7(4):347.
  • 10Rougier D, De Forni M, Adenis A, et al. Phase Ⅱ study of taxotere in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol, 1994,3(1):200.

共引文献3

同被引文献233

引证文献17

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部